Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic Melanoma

2003141 citationsJournal Article

Authors

Wen-Jen Hwu · Memorial Sloan Kettering Cancer Center

Susan E. Krown · Memorial Sloan Kettering Cancer Center

Jennifer H. Menell · Memorial Sloan Kettering Cancer Center

Katherine S. Panageas · Memorial Sloan Kettering Cancer Center

Janene Merrell · Memorial Sloan Kettering Cancer Center

Lynne Lamb · Memorial Sloan Kettering Cancer Center

Linda Williams

Abstract

The combination of temozolomide plus thalidomide seems to be a promising and well-tolerated oral regimen for metastatic melanoma that merits further study.

Topics & Keywords

Cutaneous Melanoma Detection and Management Melanoma and MAPK Pathways Multiple Myeloma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 21, Issue 17, pp. 3351-3356

DOI: 10.1200/jco.2003.02.061

Field-Weighted Citation Impact: 8.13